Agilis Robotics Completes Successful Animal Testing for Surgical Robot
Hong Kong-based Agilis Robotics Ltd has successfully completed a second round of live animal testing...
Cancer
3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...
Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...
Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication
China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical...
Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing...
Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical...
Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study
Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...
Syneos Health Partners with Fosun Pharma to Commercialize Serplulimab in US
US-based Syneos Health (Nasdaq: SYNH) has revealed a strategic partnership with Fosun Pharma USA Inc.,...
Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...
Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from...
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...
BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit
China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and...
Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics
China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc.,...
Konruns Initiates Phase II Study for KC1036 in Advanced Thymic Tumors
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the initiation of a single-arm, open,...
Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...
Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA
China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and...
Jiangsu Kanion’s KYS202002A Greenlit for Clinical Study in Multiple Myeloma
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving approval from the National...
Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...
Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong
China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...
Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review
The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...